restoring

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Digital Assets

Source Node:
Time Stamp: September 27, 2022 3:28 PM - Modified On: September 27, 2022 - Published By:
Source Cluster:
Republished By Plato

If you ask most people in crypto what a digital asset is they usually reply that it covers everything in crypto. For over a year major exchanges and projects have been asking regulators the same question and are repeatedly frustrated by their inability to answer clearly. The reason is that the term ‘digital asset’ is one you’re likely to hear or read about frequently in the coming months. According to well-placed sources within financial journalism, regulators and lobbyists backed by legacy financial institutions are gearing up to label every cryptocurrency